Van ECK Associates Corp Boosts Position in Valeant Pharmaceuticals International, Inc. (VRX)

Van ECK Associates Corp increased its holdings in shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 68.0% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 696,661 shares of the specialty pharmaceutical company’s stock after purchasing an additional 282,015 shares during the quarter. Van ECK Associates Corp owned 0.20% of Valeant Pharmaceuticals International worth $9,983,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Riggs Asset Managment Co. Inc. increased its stake in Valeant Pharmaceuticals International by 118.2% during the 3rd quarter. Riggs Asset Managment Co. Inc. now owns 8,330 shares of the specialty pharmaceutical company’s stock worth $119,000 after purchasing an additional 4,512 shares in the last quarter. Cetera Investment Advisers bought a new stake in Valeant Pharmaceuticals International during the 2nd quarter worth approximately $192,000. IPG Investment Advisors LLC bought a new stake in Valeant Pharmaceuticals International during the 2nd quarter worth approximately $203,000. Moors & Cabot Inc. increased its stake in Valeant Pharmaceuticals International by 32.3% during the 2nd quarter. Moors & Cabot Inc. now owns 15,275 shares of the specialty pharmaceutical company’s stock worth $267,000 after purchasing an additional 3,725 shares in the last quarter. Finally, US Bancorp DE increased its stake in Valeant Pharmaceuticals International by 418.4% during the 2nd quarter. US Bancorp DE now owns 15,573 shares of the specialty pharmaceutical company’s stock worth $269,000 after purchasing an additional 12,569 shares in the last quarter. 48.49% of the stock is owned by institutional investors and hedge funds.

In other news, Director John Paulson bought 344,216 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The stock was acquired at an average cost of $14.40 per share, with a total value of $4,956,710.40. Following the completion of the purchase, the director now owns 94,559 shares of the company’s stock, valued at $1,361,649.60. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 5.87% of the stock is currently owned by company insiders.

Valeant Pharmaceuticals International, Inc. (NYSE VRX) traded down $0.09 during trading hours on Monday, hitting $16.48. 6,139,402 shares of the company traded hands, compared to its average volume of 17,885,496. Valeant Pharmaceuticals International, Inc. has a twelve month low of $8.31 and a twelve month high of $18.25. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 4.84. The company has a market capitalization of $5,776.17, a PE ratio of 2.69, a PEG ratio of 0.46 and a beta of -0.40.

A number of analysts recently issued reports on VRX shares. Zacks Investment Research cut Valeant Pharmaceuticals International from a “hold” rating to a “sell” rating in a research note on Thursday, October 12th. Stifel Nicolaus reaffirmed a “buy” rating and set a $35.00 price target on shares of Valeant Pharmaceuticals International in a research note on Thursday, August 10th. Piper Jaffray Companies set a $14.00 price target on shares of Valeant Pharmaceuticals International and gave the stock a “sell” rating in a research note on Sunday, October 22nd. Vetr raised shares of Valeant Pharmaceuticals International from a “strong sell” rating to a “sell” rating and set a $12.46 price target for the company in a research note on Monday, September 18th. Finally, Cantor Fitzgerald set a $23.00 price target on shares of Valeant Pharmaceuticals International and gave the stock a “buy” rating in a research note on Wednesday, August 16th. Five equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Valeant Pharmaceuticals International has an average rating of “Hold” and an average target price of $17.17.

ILLEGAL ACTIVITY WARNING: “Van ECK Associates Corp Boosts Position in Valeant Pharmaceuticals International, Inc. (VRX)” was first posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://transcriptdaily.com/2017/11/27/van-eck-associates-corp-boosts-position-in-valeant-pharmaceuticals-international-inc-vrx.html.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply